Research Article
Prognostic Utility of Prechemoradiotherapy Albumin-to-Alkaline Phosphatase Ratio in Unresectable Locally Advanced Pancreatic Carcinoma Patients
Table 1
Baseline patient and disease characteristics for the entire study group and per low and high albumin-to-alkaline phosphatase ratio subgroups.
| | Characteristics | All patients () | L-AAPR () | H-AAPR () | value |
| | Median age (years) (range) | 59 (29-79) | 59 (29-79) | 58 (32-79) | 0.86 | | Age group, | | | | | | <70 years | 112 (82.4) | 57 (80.3) | 55 (84.6) | 0.41 | | ≥70 years | 24 (17.6) | 14 (19.7) | 10 (15.4) | | Gender, | | | | | | Female | 27 (19.9) | 15 (21.1) | 12 (19.4) | 0.62 | | Male | 109 (80.1) | 56 (78.9) | 53 (81.6) | | ECOG performance, | | | | | | 0 | 73 (53.7) | 36 (50.7) | 37 (56.9) | 0.54 | | 1 | 63 (46.3) | 35 (49.3) | 28 (43.1) | | Tumor location, | | | | | | Head | 112 (82.4) | 58 (81.7) | 54 (83.1) | 0.72 | | Body/tail | 24 (17.6) | 13 (18.3) | 11 (16.9) | | N stage, | | | | | | 0 | 69 (50.7) | 28 (39.4) | 41 (63.1) | <0.001 | | 1-2 | 67 (49.3) | 43 (60.6) | 24 (36.9) | | CA 19-9, | | | | | | ≤90 U/mL | 39 (28.7) | 13 (18.3) | 26 (28.8) | 0.001 | | >90 U/mL | 97 (71.3) | 58 (81.7) | 39 (60.1) |
|
|
Abbreviations: AAPR: albumin-to-alkaline phosphatase ratio; L-AAPR: low AAPR (<0.46); H-AAPR: high AAPR (≥0.46); ECOG: Eastern Cooperative Oncology Group; N stage: nodal stage; CA 19-9: cancer antigen 19-9; ALP: alkaline phosphatase.
|
